Drug Discovery & Development | FDA looks at possible heart failure link with AZ's Onglyza PharmaTimes The agency will review Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin/metformin) after a study published in the New England Journal of Medicine reported an increased rate of hospitalisation for heart failure with use of the drugs. The FDA ... FDA Investigating Heart Failure Risk Linked To Onglyza FDA to probe saxagliptin's heart failure risk FDA Investigating Heart Failure Risks with Saxagliptin |
